| ¿µ¹® | Raynaud disease | ÇÑ±Û | ·¹À̳뺴 |
|---|---|---|---|
| ¼³¸í | ±â´ÉÀû Ç÷°ü °æ·ÃÀ» ÀÏÀ¸Å°´Â º´À¸·Î °Ç°ÇÑ ÀþÀº ¿©¼ºÀÇ ÆÈ´Ù¸® ÀÛÀº µ¿¸ÆÀ» ħ¹üÇÑ´Ù. ÇÁ¶û½º ÀÇ»ç M.·¹À̳ë(1834~1881)°¡ º¸°íÇÑ °ÍÀ¸·Î ÀÌ º´Àº ÁÖ·Î ¼Õ°¡¶ô, ¼Õ, ¶§·Î´Â ÄÚ³¡À̳ª ¹ßµî, ¸öÀÇ ¸»´ÜºÎ ¼Òµ¿¸ÆÀ» ħ¹üÇÑ´Ù. Çѳðú °¨Á¤Àڱؿ¡ ÀÇÇÏ¸ç ¼Õ°¡¶ôÀº ¹é»öÀ¸·Î ´ÙÀ½Àº û»öÀ¸·Î, ±×¸®°í Àû»öÀ¸·Î º¯ÇÑ´Ù. ¿©¼º¿¡°Ô È£¹ßÇÑ´Ù. |
||
| ¿µ¹® | rheumatic heart disease | ÇÑ±Û | ·ù¸¶Æ¼½º½ÉÀ庴 |
|---|---|---|---|
| ¼³¸í | »ç½½¾Ë±Õ°¨¿° ÈÄ »ý±â´Â ½ÉÀåÆÇ¸·º´ÀÌ´Ù. ¿øÀÎÀº A±º -¿ëÇ÷»ç½½¾Ë¿¡ ÀÇÇÑ Àεο°ÈÄ ÀÏÁ¾ÀÇ ¸é¿ª¹ÝÀÀÀ¸·Î ¹ßº´ÇÑ´Ù. Áø´ÜÀº Á¸ÀÇ ±âÁØ¿¡ ÀÇÇÑ´Ù. (1) ÁÖ¿ä±âÁØÀº °üÀý¿° ½ÉÀå¿°(½ÉÀåºñ´ë, ½ÉÀåÀâÀ½, ½ÉÀå±â´É»ó½Ç µî) ¹«µµÁõ: ¹«´çÀÌ ÃãÀ» Ãß´Â °Í °°Àº ÇൿÀÇ ¹ßÀÛÁõ¼¼. ¿¬º¯È«¹Ý: »¡°£ Å׵θ®¸¦ °¡Áø ÇǺκ´º¯Àº ÇÇÇϰáÀý(subcutaneous nodule): ÇǺΠ¹Ø¿¡ »ý±ä °áÀý, (2)Âü°í ±âÁØÀº ¿, °üÀýÅë, EKG»ó PR¿¬Àå: ½ÉÀüµµ ¼Ò°ß ±Þ¼º±â ¹ÝÀÀ¹°Áú(¿¹: ESR, CRP)ÀÇ »ó½Â, ·ù¸¶Æ¼½º¿ Ä¡·á´Â Æä´Ï½Ç¸°À¸·Î Ä¡·áÇÏ°í ½ÉÀåÀÇ ÈÄÀ¯Áõ ¶ÇÇÑ Æä´Ï½Ç¸°À¸·Î ¿¹¹æÇÑ´Ù. |
||
| ¿µ¹® | chronic obstructive pulmonary disease | ÇÑ±Û | ¸¸¼ºÆó¼âÆóº´ |
|---|---|---|---|
| ¼³¸í | ¸¸¼ºÀûÀ¸·Î ±âµµÀÇ Æó¼â¸¦ °¡Á®¿À´Â º´À» À̸£´Â ¸». ´ë°³ ¸¸¼º±â°üÁö¿°, ±â°üÁö õ½Ä, Æó±âÁ¾ÀÇ 3°¡Áö º´À» ¸»ÇÑ´Ù. ¸¸¼º±â°üÁö¿°À̶õ ±â°üÁöÀÇ ¸¸¼º¿°ÁõÀ» ¸»ÇÑ´Ù. ±â°üÁöÀÇ ¿°ÁõÀ¸·Î ÀÎÇØ¼ ±â°üÁöÀÇ Á¡¸·¿¡ ºÎÁ¾ÀÌ »ý±â°í ÀÌ·Î ÀÎÇØ¼ ±â°üÁöÀÇ ³»°æÀÌ Á¼¾ÆÁ®¼ ±âµµÀÇ Æó¼â¸¦ °¡Á®¿Â´Ù. ´ë°³ Èí¿¬°ú ¹ÐÁ¢ÇÑ ¿¬°üÀ» °¡Áö¸ç, È£Èí°ï¶õ, ±âħ, ±×¸®°í °¡·¡(´ë°³ »öÀÌ Çª¸£°í Á¡µµ°¡ ³ôÀº °¡·¡)°¡ Áõ»óÀ¸·Î ³ªÅ¸³´Ù. Æó±âÁ¾Àº ±â°üÁöÀÇ º®À» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ ±â°üÁö°¡ Á¦ ¸ð¾çÀ» °®ÃßÁö ¸øÇÏ°í ¹«³ÊÁö°Ô µÇ¾î ±âµµÀÇ Æó¼â°¡ ÀϾ´Â º´ÀÌ´Ù. Áï ±â°üÁö°¡ °ü ¸ð¾çÀ¸·Î ÆØÆØÇÏ°Ô ÆìÁö´Â °ÍÀ» ÁöÁöÇÏ´Â Á¶Á÷ÀÇ ÆÄ±«¿¡ ÀÇÇØ¼ °ü¸ð¾çÀ¸·Î ÆìÁöÁö ¸øÇØ °á±¹Àº ÆóÆ÷³»¿¡ °ø±â°¡ Â÷°í ÆóÆ÷º®ÀÌ ÆÄ¿µÇ°í ±â°üÁö°¡ Á¼¾ÆÁö°Ô µÇ´Â º´À» ¸»ÇÑ´Ù. ±â°üÁöõ½ÄÀ̶õ ¿©·¯ °¡Áö Àڱؿ¡ ´ëÇØ¼ ±â°üÁö°¡ °ú¹ÎÇÑ ¹ÝÀÀÀ» º¸¿©¼ »ý±â´Â ±â°üÁöÀÇ °¡¿ªÀûÀÎ Æó¼â¸¦ ÀǹÌÇÑ´Ù. Áï Á¤»óÀο¡°Ô¼´Â ±â°üÁöÀÇ Æó¼â¸¦ º¸ÀÌÁö ¾Ê´Â Àڱؿ¡ ´ëÇØ¼ ±â°üÁöÀÇ Æó¼â°¡ »ý±â°í ±× ÀÚ±ØÀÌ ¾øÀ» °æ¿ì¿¡´Â ±â°üÁöÀÇ Æó¼â°¡ ¾ø¾îÁö´Â º´À» ¸»ÇÑ´Ù. |
||
| ¿µ¹® | Buerger disease | ÇÑ±Û | ¹ö°Åº´ |
|---|---|---|---|
| ¼³¸í | ¸»ÃÊ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀ» ÀÏÀ¸Å°´Â º´. ûÀå³âÃþÀÇ ³²ÀÚ¿¡°Ô Àß °É¸®´Â ´Ù¸® µ¿¸Æ¿¡ »ý±â´Â º´À¸·Î µ¿¸ÆÀÌ ¸·È÷°í ÅëÁõ ¶§¹®¿¡ ¹ßÀ» Àý±âµµ Çϴµ¥ ¿øÀÎÀº ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù. º´¸íÀº ÀÌ º´À» ÃÖÃÊ·Î »ó¼¼ÇÏ°Ô º¸°íÇÑ ¹Ì±¹ÀÇ ÀÇ»ç L. ¹ö°Å(1879~1943)ÀÇ À̸§¿¡¼ ¿¬À¯ÇÑ´Ù. µ¿¾çÀο¡°Ô ¸¹Àº º´À¸·Î, ´ëºÎºÐ ÀþÀº ³²¼º, ƯÈ÷ Àå³â±â ³²¼º¿¡°Ô¼ ³ªÅ¸³´Ù. ¿øÀÎÀº ¾Ë ¼ö ¾øÀ¸³ª Èí¿¬ÀÌ º´ÀÇ ¾Çȸ¦ ÃÊ·¡ÇÑ´Ù. »çÁöÀÇ µ¿¸Æ°ú Á¤¸Æ¿¡ ¿°ÁõÀÌ ÀϾ Ç÷ÀüÀÌ »ý±â¸é ³»°À» ¸·¾Æ Ç÷¾×ÀÌ È帣Áö ¸øÇÏ°Ô µÇ¾î ±× ¾ÕÀÇ ¸»ÃÊÁ¶Á÷ÀÌ ±«»ç¿¡ ºüÁö°Å³ª ¼Õ¹ßÀÌ Â÷°©°í, ¼Õ°¡¶ô-¹ß°¡¶ôÀÌ º¸¶ó»ö ¶Ç´Â °ËÀº»öÀ¸·Î º¯ÇÑ´Ù. ¶Ç, ÀÌ Áõ¼¼°¡ °è¼ÓµÇ´Â µ¿¾È ¼Õ¹ß°¡¶ô¿¡ ÅëÁõÀÌ ÀϾ°í ±Ë¾çÀÌ ¹ß»ýÇÑ´Ù. Ä¡·á´Â Áõ¼¼ÀÇ Á¤µµ¿Í Æó»öµÈ Ç÷°üÀÇ ºÎÀ§¿¡ µû¶ó ¿¬°í¸¦ ¹Ù¸£°Å³ª Ç÷°üÈ®ÀåÁ¦-¼øÈ¯°³¼±Á¦-Ç÷¼ÒÆÇÀÀÁý¾ïÁ¦Á¦¸¦ »ç¿ëÇϳª, ¾î¶² Ä¡·áµµ È¿°ú°¡ ¾øÀ» °æ¿ì ¼Õ¹ß°¡¶ôÀÇ ¼ÒÀý´Ü, µå¹°°Ô´Â ¹«¸ ÀÌÇÏÀÇ ´ëÀý´ÜÀ» ÇØ¾ß ÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ º´ÀÇ ¿¹ÈÄ´Â ¾çÈ£ÇÏ¿© Ç÷·ù°¡ ȸº¹µÇ°í ±Ë¾ç¸¸ Ä¡·áµÇ¸é Àç¹ßÀÌ Àû´Ù. |
||
| ¿µ¹® | Behcet disease | ÇÑ±Û | º£Ã¼Æ®º´ |
|---|---|---|---|
| ¼³¸í | ½ÉÇÑ Æ÷µµ¸·¿°, ¸Á¸·Ç÷°ü¿°, ½Ã°¢½Å°æÀ§Ãà, ±¸°-¼º±âÀÇ ¾ÆÇÁŸ¼º ±Ë¾ç, ±¤¹üÀ§ÇÑ Ç÷°ü¿°ÀÇ Â¡ÈÄ¿Í Áõ»óÀ» ³ªÅ¸³½´Ù. ¿øÀκҸíÀÇ Èñ±ÍÇÑ º´À¸·Î ÀþÀº ³²ÀÚ¿¡°Ô Àß ¹ß»ýÇÑ´Ù. |
||
| TAPVR | Total Anomalous Pulmonary Venous Return = TAPVC 4 Types of TAPVR &... |
|---|---|
| CD | cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise... |
| HD | Haab-Dimmer [syndrome]; Hajna-Damon [broth]; Hansen disease; hearing distance; heart disease; helix ... |
| MD | Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major... |
| AD | accident dispensary; acetate dialysis; active disease; acute dermatomyositis; addict, addiction; ade... |
| disease, lipid storage | A series of disorders due to inborn errors in lipid metabolism resulting in the abnormal accumulation of lipids in the wrong places (Examples include Gaucher, Fabry and Niemann-Pick diseases and metachromatic leukodystrophy). (12 Dec 1998) |
|---|---|
| disease, phytanic acid storage | A genetic disorder of the fatty acid phytanic acid which accumulates and causes a number of progressive problems including polyneuritis (inflammation of numerous nerves), diminishing vision (due to retinitis pigmentosa), and wobbliness (ataxia) caused by damage to the cerebellar portion of the brain (cerebellar ataxia).(refsum's disease) (12 Dec 1998) |
| iron-storage disease | The storage of excess iron in the parenchyma of many organs, as in idiopathic haemochromatosis or transfusion haemosiderosis. (05 Mar 2000) |
| annexin vii | Protein of the annexin family that promotes the aggregation and fusion of chromaffin granules and can also act as a voltage-dependent calcium channel. (12 Dec 1998) |
| mucopolysaccharidosis vii | Mucopolysaccharidosis characterised by excessive dermatan and heparan sulfates in the urine and hurler-like features. It is caused by a deficiency of beta-glucuronidase. (12 Dec 1998) |
| cranial mononeuropathy vii | A disorder which involves drooping of the face and the decreased ability to move one side of the face. Causes include isolated damage to the facial nerve, HIV infection, sarcoidosis and Lyme disease. Bell's palsy is a dysfunction of the facial nerve for reason unknown. (27 Sep 1997) |
| cranial nerve VII | <anatomy, nerve> The facial nerve enervates the muscles of the face (facial expression). Lesion of the facial nerve cause a drooping to one side of the face, inability to wrinkle the forehead, inability to whistle, inability to close the eye and deviation of the mouth to the unaffected side. Synonym: cranial nerve VII. (27 Sep 1997) |
| exonuclease vii | An exonuclease enzyme which makes oligonucleotides by cleaving chunks of nucleotides off of both ends of single-stranded DNA. (09 Oct 1997) |
| factor vii | <chemical> Heat- and storage-stable plasma protein that is activated by tissue thromboplastin to form factor viia in the extrinsic pathway of blood coagulation. The activated form then catalyses the activation of factor x to factor xa. Chemical name: Blood-coagulation factor VII (12 Dec 1998) |
| factor vii assay | A test used to measure the activity of a blood clotting factor VII. This test may be used to evaluate excessive bleeding. Abnormally low factor VII assays may be seen in the following conditions: congenital deficiency of factor VII, fat malabsorption, heparin administration, cirrhosis, vitamin K deficiency and warfarin administration. (27 Sep 1997) |
| factor vii deficiency | An inherited disorder that causes abnormal blood clotting due to the congenital absence of one of the 20 different plasma proteins involved in the coagulation process. Symptoms include bleeding of the gums, nosebleeds, easy bruising, bleeding in muscles or joints and excessive menstrual bleeding. Treatment includes the administration of plasma concentrates of factor VII (extrinsic factor). (27 Sep 1997) |
| glycogen | <biochemistry> Branched polymer of D glucose (mostly _(1-4) linked, but some _(1-6) at branch points). Size range very variable, up to 10exp5 glucose units. Major short term storage polymer of animal cells and is particularly abundant in the liver and to a lesser extent in muscle. In the electron microscope glycogen has a characteristic asterisk or star appearance. (18 Nov 1997) |
| glycogen debranching enzyme system | 1,4-alpha-d-glucan-1,4-alpha-d-glucan 4-alpha-d-glucosyltransferase/dextrin 6 alpha-d-glucanohydrolase. An enzyme system having both 4-alpha-glucanotransferase (ec 2.4.1.25) and amylo-1,6-glucosidase (ec 3.2.1.33) activities. As a transferase it transfers a segment of a 1,4-alpha-d-glucan to a new 4-position in an acceptor, which may be glucose or another 1,4-alpha-d-glucan. As a glucosidase it catalyses the endohydrolysis of 1,6-alpha-d-glucoside linkages at points of branching in chains of 1,4-linked alpha-d-glucose residues. Amylo-1,6-glucosidase activity is deficient in glycogen storage disease type III. (12 Dec 1998) |
| glycogen granule | Glycogen occurring in cells as beta granule's which average about 300 A |
| glycogen phosphorylase | <enzyme> Enzyme that catalyses the sequential removal of glycosyl residues from glycogen to yield one glucose-1-phosphate per reaction. Its activity is controlled by phosphorylation (by phosphorylase kinase). (21 Jun 2000) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|